ARTICLE | Product Development
Amgen deal gives BeiGene dry powder to grow its own pipeline
Amgen deal gives BeiGene more firepower to add to its pipeline via BD and discovery
October 31, 2019 8:09 PM UTC
Updated on Nov 6, 2019 at 7:23 PM UTC
In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed portfolio and R&D pipeline. The partnership could deliver BeiGene its goal of becoming a global player.
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) will co-develop 20 programs from the cancer pipeline of Amgen Inc. (NASDAQ:AMGN) in China and gain commercialization rights to the U.S. company’s three marketed cancer products. ...